• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OptiNose raises $37m in Series D for commercial efforts

May 9, 2017 By Sarah Faulkner

OptiNoseOptiNose said today that it closed a $37 million Series D round led by Fidelity Management and Research Company. Avista Capital Partners, Entrepreneurs Fund and other current investors also contributed to the round.

The Yardley, Penn.-based company said it plans to use the newly-acquired funds to support commercial development of its lead product candidate, OPN-375, in the U.S.

OptiNose’s 1st commercial product is based on its Breath Powered platform, which the company said it uses to develop new systems capable of deep intranasal deposition of medication. The company’s lead candidate, OPN-375, is a delivery device with fluticasone propionate and is being designed to treat nasal diseases with chronic inflammation deep in the nose, including nasal polyposis and chronic sinusitis.

“We are building a company dedicated to meeting the needs of patients treated by ENT/allergy specialists and using our patented technology and other approaches to create innovative products that improve clinical outcomes and make lives better,” CEO Peter Miller said in prepared remarks. “Chronic rhinosinusitis with or without nasal polyps, our current focus, is a large market worldwide. Data suggest there is tremendous dissatisfaction with the current medical treatment options.”

“This is a serious disease, and it causes a high degree of suffering for millions of people in the U.S. alone. OPN-375 could fill an important role in the care pathway for the many patients who do not get satisfactory relief with current treatments,” president & COO Ramy Mahmoud added. “We have an excellent team that is eager to make this product available to patients, and this latest round of funding will put us in a position to make the investments needed to ensure that, if approved, we are ready for launch in the 1st half of 2018.”

OptiNose said it submitted a new drug application to the FDA in November last year and the regulatory watchdog is slated to finish its review in September.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory Tagged With: OptiNose

IN CASE YOU MISSED IT

  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS